March 2021 tender notification

Medicines

Tender Closed

PHARMAC is pleased to provide the latest tender results.

Tender results

PHARMAC has resolved to award tenders for Principal Supply Status for some products included in the 2020/21 Invitation to Tender, dated 2 November 2020 and has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2018/19 Invitation to Tender, dated 1 November 2018.

Some of the pharmaceuticals that will be delisted when the period of Principal Supply Status, Sole Subsidised Supply Status, Hospital Supply Status (as relevant) commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to PHARMAC, the Pharmacy Guild and the NZULM by:

  • For new listings, by 4pm on 12 April 2021 or the 5th of the month prior to listing, whichever is earlier
  • For price changes, by 4pm on the 12th of the month prior to the date of subsidy change

PHARMAC cannot list a product (and pharmacies cannot claim) without this information. 

More information about this process and NOPC forms can be found on our website.

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link)  and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link).

Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest).

PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.

2018/19 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2022

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current
pack price

New
pack price

Sole supply brand (Supplier)

Date of listing

Sole Subsidised Supply date

Levonorgestrel

Tab 1.5 mg; 1 tab pack

$4.95

$4.95

Postinor-1
(Bayer New Zealand Ltd)

1 October 2021

1 March 2022

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

2.  Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current
pack price

New
pack price

Sole supply brand (Supplier)

DV limit

Date of listing

Hospital Supply Status date

Levonorgestrel

Tab 1.5 mg; 1 tab pack

$4.95

$4.95

Postinor-1
(Bayer New Zealand Ltd)

1%

1 October 2021

1 March 2022

 

2020/21 Tender – Principal Supply Status applies until 30 June 2024

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

3.  Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current
pack price

New
pack price

Principal Supply brand
(Supplier)

Date of subsidy change

Principal Supply date

Aprepitant1

Cap 2 x 80 mg and 1 x 125 mg; 3 capsule OP blister pack

$84.00

$30.00

Emend Tri-pack

(Merck Sharp & Dohme (New Zealand) Limited)

1 July 2021

1 December 2021

Brimonidine tartrate1

Eye drops 0.2%; 5 ml OP dropper bottle

$12.25

$4.29

Arrow – Brimonidine (Teva Pharma New Zealand Ltd)

1 August 2021

1 January 2022

Disulfiram1

Tab 200 mg; 100 tablet blister pack

$250.00

$236.40

Antabuse

(Teva Pharma New Zealand Ltd)

1 June 2021

1 November 2021

This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 5, clause 3.1 (b)(II) of the 2020/21 Invitation To Tender.

4.  Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current
pack price

New
pack price

Principal Supply brand (Supplier)

Date of listing

Principal Supply Status date

Brand (Supplier) affected by delisting

Ibuprofen

Tab long-acting 800 mg; 30 tablet blister pack

$5.99

$3.05

Brufen SR (Mylan New Zealand Ltd)

1 August 2021

1 January 2022

Ibuprofen SR BNM
(Boucher and Muir (NZ) Limited)

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule.

5.  Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current
pack price

New
pack price

Principal Supply brand
(Supplier)

DV
limit

Date of subsidy change

Principal Supply date

 

Aprepitant2

Cap 2 x 80 mg and 1 x 125 mg; 3 blister pack

$84.00

$30.00

Emend Tri-pack (Merck Sharp & Dohme (New Zealand) Limited)

5%

1 July 2021

1 December 2021

 

Brimonidine tartrate2

Eye drops 0.2%, 5 ml dropper bottle

$12.25

$4.29

Arrow – Brimonidine (Teva Pharma New Zealand Ltd)

5%

1 August 2021

1 January 2022

 

Disulfiram2

Tab 200 mg; 100 tablet, blister pack

$250.00

$236.40

Antabuse (Teva Pharma New Zealand Ltd)

5%

1 June 2021

1 November 2021

 

This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 6, clause 3.1 (b)(II) of the 2020/21 Invitation To Tender.

 6.  Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current
pack price

New
pack price

Principal Supply brand (Supplier)

DV limit

Date of listing

Principal Supply Status date

Brand (Supplier) affected by delisting

Ibuprofen

Tab long-acting 800 mg; 30 tablet blister pack

$5.99

$3.05

Brufen SR (Mylan New Zealand Ltd)

5%

1 August 2021

1 January 2022

Ibuprofen SR BNM
(Boucher and Muir (NZ) Limited)

Tender declines - Products where no tender is to be awarded for Principal Supply Status

PHARMAC has resolved not to award tenders for Principal Supply Status for the following products listed in the 2020/21 Invitation to Tender, dated 2 November 2020

2020/21 Invitation to Tender

Chemical name

Line item

Amphotericin B

Liposomal inj 50 mg

Aprepitant (widened access)

Cap 2 x 80 mg and 1 x 125 mg

Benzbromarone

Tab 25 - 100 mg

Cidofovir

Inj 75 mg per ml, 5 ml

Ciprofloxacin

Inj 2 mg per ml, 100 ml

Diltiazem Hydrochloride

Inj 5 mg per ml, 5 ml vial

Diltiazem hydrochloride

Tab 30 mg

Diltiazem hydrochloride

Tab 60 mg

Doxorubicin

Inj 10 mg

Doxorubicin

Inj 100 mg

Doxorubicin

Inj 50 mg

Gentamicin sulphate

Inj 10 mg per ml, 1 - 2 ml

Gentamicin Sulphate

Inj 40 mg per ml, 2 ml

Glyceryl trinitrate

Tab sublingual 600 mcg

Haloperidol decanoate

Inj 100 mg per ml, 1 ml

Haloperidol decanoate

Inj 50 mg per ml, 1 ml

Hydrocortisone

Oral liq

Hydrocortisone

Tab 1 mg

Hydrocortisone

Tab 20 mg

Hydrocortisone

Tab 4 mg

Hydrocortisone

Tab 5 mg

Loperamide hydrochloride [split market]

Tab 2 mg

Metformin Hydrochloride

Cap/tab sustained-release 1 g

Metformin Hydrochloride

Cap/tab sustained-release 500 mg

Methadone hydrochloride

Inj 10 mg per ml, 1 ml

Metronidazole

Gel 0.75%

Morphine Hydrochloride

Oral liq 1 mg per ml

Morphine Hydrochloride

Oral liq 10 mg per ml

Morphine Hydrochloride

Oral liq 2 mg per ml

Morphine Hydrochloride

Oral liq 5 mg per ml

Nitrazepam

Tab 5 mg

Norfloxacin

Tab 400 mg

Pizotifen

Tab 500 mcg

Potassium citrate

Tab

Tenecteplase

Inj 50 mg

Terlipressin

Inj 0.2 mg per ml, 10 ml

Ziprasidone

Cap 20 mg

Ziprasidone

Cap 40 mg

Ziprasidone

Cap 60 mg

For products included in the 2018/19, 2019/20 or 2020/21 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.